RELATED APPLICATIONS The present patent document claims the benefit of the filing date under 35 U.S.C. §119(e) of Provisional U.S. Patent Application Ser. 60/903,116, filed Feb. 23, 2007, which is hereby incorporated by reference. FIELD The present invention relates to the field of diagnostics. More particularly, the invention disclosed herein is directed to methods, compositions, and kits for detecting nucleic acids, polynucleotides, pathogens, toxins, or other agents or factors that are desirably detected or measured.

Anytime without any prior notice. Removed according to Cunningham's Manual of. Lauretti L, Del Giudice G, Zoratti M Polyphenols.

BACKGROUND There is a great need to detect and quantify various molecular species, such as polynucleotides, polypeptides, carbohydrates, lipids, and small molecules. For example, current methods of detecting a polynucleotide, such as those associated with pathogens, pathogen infection, human genes associated with diseases and disorders, altered physiology or physiological conditions, genetically modified organisms (GMOs, i.e., organisms with transgenic DNA), biowarfare agents, veterinary applications, and agricultural applications presently rely on complex methods, such as the polymerase chain reaction (PCR), nucleic acid sequence-based amplification (NASBA), transcription-mediated amplification (TMA), or branched DNA (bDNA). These methods require skilled personnel and specialized equipment. Further, the methods are generally incapable of determining the presence or quantity of polynucleotides in crude cell and tissue extracts.

There are similar difficulties in the existing immunoassays for detecting antigens. In formula (II), independently at each occurrence, R 1 and R 2 are each independently selected from C 1-C 6 alkyl, C 2-C 6 alkenyl, and C 2-C 6 alkynyl; R 3 is selected from the group consisting of hydrogen, C 1-C 6 alkyl, C 2-C 6 alkenyl, and C 2-C 6 alkynyl, C 6-C 10 aryl, hydroxyl, alkoxy, carbonyl, sulfinyl, sulfonyl, and amino groups; n is 1 or 2; R 4 and R 9 are each independently selected from the group consisting of H, C 1-C 6 alkyl, C 2-C 6 alkenyl, C 2-C 6 alkynyl, C 6-C 10 aryl, hydroxyl, alkoxy, halo, carbonyl, sulfinyl, sulfonyl, and amino groups. In a further embodiment, the dye is a compound that is represented by the formula (III), or a salt or ester thereof. Where X- is an anion. More preferably, the anion is a halogen; yet more preferably, the anion is iodide. In one embodiment of formula (I, II, and III), n is 0. In another embodiment of formula (I, II, and III), n is 1.

In another embodiment of formula (I, II, and III), n is 2. Jackson 5 anthology rar download. In yet another embodiment of formula (I, II, and III), n is 3. In one embodiment of formula (I, II, and III), R 1 and R 2 are each independently selected from group consisting of hydrogen, alkyl, alkenyl, alkynyl, heteroalkyl, heteroalkenyl, heteroalkynyl, aryl, and heteroaryl. In another embodiment of formula (I, II, and III), R 1 and R 2 are each independently selected from group consisting of alkyl, alkenyl, alkynyl, heteroalkyl, heteroalkenyl, and heteroalkynyl. In another embodiment of formula (I, II, and III), R 1 and R 2 are each independently selected from group consisting of alkyl, alkenyl, and alkynyl.

In another embodiment of formula (I, II, and III), R 1 and R 2 are each independently alkyl. In one embodiment of formula (I, II, and III), R 3 is selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, heteroalkyl, heteroalkenyl, and heteroalkynyl.

In one embodiment of formula (I, II, and III), R 3 is selected from the group consisting of alkyl, alkenyl, and alkynyl. In one embodiment of formula (I, II, and III), R 3 is alkyl. The compounds in the following list are within the scope of formulas (I-III.

: The AMEDEO Literature Guide Language recovery after stroke (278 pp) Neurosurgery Articles published in Neurosurgery Retrieve available abstracts of 1428 articles: Single Articles March 2019• KOCHANEK PM, Tasker RC, Carney N, Totten AM, et al Guidelines for the Management of Pediatric Severe Traumatic Brain Injury, Third Edition: Update of the Brain Trauma Foundation Guidelines, Executive Summary. Pii: 5367430. Doi: 10.1093.

Abstract available • HOSHIDE R, Jandial R Blueprints for a New Spinal Cord. • PATEL NV, Schneider JR, Kwan K, Boockvar JA, et al Phenotypic Transformation of Astrocytes Into Tumor-Supportive Cells: Glioblastoma Cell Vesicle Release. • QADDOURA A, Shalung TN, Meier MP, Goguen J, et al Recovery Room Cortisol Predicts Long-Term Glucocorticoid Need After Transsphenoidal Surgery for Pituitary Tumors. Abstract available February 2019• GODINHO F, Magnin M, Filho PT, Reis P, et al Stereotactic Lesion in the Forel's Field H: A Two-Years Prospective Open-Label Study on Motor and Nonmotor Symptoms, Neuropsychological Functions and Quality of Life in Parkinson Disease. Pii: 5366465. Doi: 10.1093. Abstract available • SHANK CD, Erickson NJ, Miller DW, Lindsey BF, et al Reserved Bed Program Reduces Neurosciences Intensive Care Unit Capacity Strain: An Implementation Study.